Roche has obtained the US Food and Drug Administration (FDA) priority review for its supplemental Biologics License Application (sBLA) for intravenous Actemra/RoActemra (tocilizumab) to treat Covid-19.

A humanised interleukin-6 (IL-6) receptor antagonist, Actemra/RoActemra is currently approved to treat moderately to severely active rheumatoid arthritis (RA) in adults.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The treatment is intended for hospitalised Covid-19 adult patients who are taking systemic corticosteroids and need supplemental oxygen.

These patients also require non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.

Roche anticipates a decision on approval from the regulatory agency in the second half of this year.

The submission of the application was based on findings from four controlled, randomised clinical trials that assessed Actemra/RoActemra to treat Covid-19 in over 5,500 patients in the hospital.

Data from the EMPACTA, COVACTA, REMDACTA and RECOVERY trials suggest that the treatment could boost outcomes in subjects who are taking corticosteroids and need supplemental oxygen or breathing support.

In June last year, the FDA granted Emergency Use Authorization for Actemra/RoActemra, which is also approved in 16 countries globally for severe or critical Covid-19 patients in the hospital.

Earlier, Actemra/RoActemra obtained World Health Organization (WHO) prequalification in February this year for use in severe or critical Covid-19 patients, facilitating its access in low- and middle-income nations.

Roche Global Product Development chief medical officer and head Levi Garraway said: “The high rate of unvaccinated people will continue to put a strain on hospitals and healthcare systems around the world, furthering the need for effective treatments for patients hospitalised with Covid-19.

“More than one million people with severe or critical Covid-19 have already been treated with Actemra/RoActemra worldwide, demonstrating the important role of this medicine in the fight against the pandemic.”